Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-PAD2 mAb
- Development stage
- Preclinical
- Lead developer
- Pharma Foods International
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Anti-PAD2 mAb is a chicken-derived monoclonal antibody developed by Pharma Foods International using its proprietary ALAgenе® technology platform. It specifically targets protein arginine deiminase 2 (PAD2), an enzyme that converts arginine residues in proteins to citrulline. Aberrant PAD2 activity and subsequent protein citrullination are linked to the pathogenesis of various cancers and autoimmune disorders. This antibody is designed to bind to a specific epitope on PAD2 with high affinity (nanomolar range) and inhibit its extracellular enzymatic activity. By neutralizing PAD2, the therapy aims to suppress tumor-promoting processes associated with dysregulated citrullination. The drug is currently in the preclinical stage of development for cancer treatment.
- Other names
- anti-PAD2 monoclonal antibodyanti-PAD-2 monoclonal antibodyanti-PAD 2 monoclonal antibodyPAD2-monoclonal antibodyPAD-2-monoclonal antibodyPAD 2-monoclonal antibody
02
Targets
PADI2 (Peptidyl arginine deiminase 2)
Beyond the preview
Go deeper on Anti-PAD2 mAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-PAD2 mAb.